Navigation Links
Experimental gene therapy 'abolishes' arthritis pain and lessens joint damage

Early-stage research has found that a new gene therapy can nearly eliminate arthritis pain, and significantly reduce long-term damage to the affected joints, according to a study published today in the journal Arthritis and Rheumatism. While the study was done in mice, they are the first genetically engineered to develop osteoarthritis like humans, with the same genetic predisposition that makes some more likely to develop the disease, the authors said. If all goes well with a follow-up study currently underway, researchers will apply to the U.S. Food and Drug Administration for permission to begin human trials next year.

Nearly everyone aged 65 or older suffers from the pain, swelling and permanent joint damage of osteoarthritis. The most common form of arthritis, it develops over time following initial joint injuries or just as a result of aging. In the current study, researchers found that one injection of a newly designed gene therapy relieved 100 percent of osteoarthritic pain in the study model. In addition, researchers were surprised to find that the therapy also brought about a nearly 35 percent reduction in permanent structural to joints caused by round and after round of osteoarthritic inflammation.

To date, treatment of arthritis is dominated by drug treatments like non-steroidal, anti-inflammatory drugs, COX-2 inhibitors and acetominophen. Morphine and its derivatives are still in common use as well, but can depress breathing and lead to addiction. Taken together, current treatments deliver inconsistent results and new approaches are needed, researcher said. Gene therapy has been attempted in the past, but older, invasive techniques required that therapeutic genes be injected directly into nerve cells. Strong pain relief resulted, but in some cases the injections caused nerve damage.

"Our publication represents the first proof that gene therapy can work in a way that is clinically applicable," said Stephanos Kyrkanides, D.D.
'"/>

Source:University of Rochester Medical Center


Page: 1 2 3 4

Related biology news :

1. NIAID Initiates Trial of Experimental Avian Flu Vaccine
2. Experimental shingles vaccine proves effective in nationwide study
3. Experimental vaccine protects nonhuman primates when given after exposure to Marburg virus
4. Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
5. Experimental drug reverses key cognitive deficits, pathology in Alzheimers
6. Experimental RNA-based drug kills prostate cancer cells effectively and safely
7. Experimental vaccine protects lab animals against several strains of H5N1
8. Experimental vaccine protects mice against deadly 1918 flu virus
9. Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy
10. Experimental vaccine given during pregnancy reduces stillbirths from common virus
11. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
Post Your Comments:
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
(Date:5/8/2015)... -- Synaptics Inc. (NASDAQ: SYNA ), the leading developer ... executive management team will present at the following investor events: ... Conference Date: May 18, 2015 Time: 10:40am ET ... Cowen and Company Technology, Media & Telecom ... New York Palace Hotel, New York, NY ...
(Date:4/27/2015)... 27, 2015  For more than four decades, AUVSI,s ... been the premier worldwide event for the unmanned land, ... must-attend event for any local, national, or trade news ... commercial markets and current applications of unmanned technologies. The ... projected $48 billion industry, and how it will soon ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Synaptics to Present at Upcoming Investor Conferences 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... genetic techniques led by Adelaide researchers are making it ... protected rainforests. DNA fingerprinting for timber products has ... the University of Adelaide that traces individual ... they came from. Professor Andrew Lowe, Director of ...
... the Institute of Food Research and The Genome Analysis ... bacterium, to help understand how these organisms evolved their ... gut bacteria and the gastrointestinal tract is one of ... of bacteria in establishing and maintaining gut health is ...
... think nicotine receptors are only important to smokers trying ... published in the FASEB Journal ( http://www.fasebj.org ... role in social interaction and the ability to choose ... the nicotinic receptors in the prefrontal cortex are essential ...
Cached Biology News:Using DNA in fight against illegal logging 2Genome analysis will reveal how bacteria in our guts make themselves at home 2Your brain on nicotine: Nicotine receptors affect social behavior 2
(Date:5/21/2015)... uBiome, the leading startup focused ... PicnicHealth, a healthcare company that collects and consolidates ... Bowel Disease (IBD) will receive a complementary PicnicHealth ... kit. Both companies were funded by Y Combinator ... more information on this partnership and how to ...
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
(Date:5/21/2015)... 2015 Tunnell Consulting, Inc. ... as senior statistician and Principal, a position to which ... the management and analysis of complex and large data ... , “We’re delighted to have Julia join the Tunnell ... said Dr. Philippe Cini, Group Vice President and leader ...
(Date:5/20/2015)... , May 20, 2015  Select Medical Corporation ... Federal Trade Commission granted early termination of the ... Act of 1976, as amended, applicable to the ... Corporation, a joint venture that Select has created ... As previously announced, MJ Acquisition Corporation has ...
Breaking Biology Technology:uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... released its upcoming schedule of CLE accredited,teleconferences for tort litigators, ... , , Upcoming teleconferences include:, ... the State of the Art., February ... February 5 - Nanotechnology: Is it the Next Plastics or ...
... NEW YORK, Jan. 20 Immtech Pharmaceuticals, Inc. ... Company has appointed Virchow, Krause & Company, LLP ... immediately. The decision to change the Company,s independent ... Company,s board of directors. The appointment will ...
... REYKJAVIK, Iceland, Jan. 20 deCODE genetics (Nasdaq: ... agreement with NBI, an Icelandic financial institution, pursuant to which ... price of $11 million. Pursuant to the agreement, deCODE has ... back to the company at any time prior to December ...
Cached Biology Technology:Asbestos, Pharmaceutical Liability, Construction Defects, Nanotech: Covered by Targeted CLE Teleconferences 2Immtech Announces Appointment of Virchow Krause as Independent Registered Public Accounting Firm 2deCODE Sells Auction Rate Securities 2deCODE Sells Auction Rate Securities 3
Monoclonal antibodies conjugated with rhodamine...
... to Rhodopsin Rhodopsin is a glycoprotein ... birds, amphibians, and reptiles. The rhodopsin protein ... the retina. Immunogen: Membrane ... Specificity: This antibody specifically labels the ...
... 3′-(α-Amino- p- methoxyhydrocinnamamido)-3′-deoxy-N,N-dimethyladenosine, 2HCl ... PROTECT FROM MOISTURE. Protein synthesis inhibitor. ... of nascent polypeptide chains. Induces DNA ... HL-60 leukemia cells. Purity: ≥98% ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
Biology Products: